[ad_1]
HYDERABAD: Vaccine maker Bharat Biotech has joined hands with Serum Institute of India’s (SII) wholly-owned Dutch subsidiary Bilthoven Biologicals BV (BBio) for the procurement of drug substances for the production of oral polio vaccines for the Indian as well as global markets.
Bharat Biotech and Bilthoven Biologicals, who have entered into an agreement, will jointly obtain the regulatory approvals and licenses required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at Bilthoven Biologicals, a joint statement by Bharat Biotech and SII said.
Commenting on the development, SII CEO Adar Poonawalla said “We are delighted to join forces with Bharat Biotech to reinforce the global supply of polio vaccines. Our vision is to eradicate polio worldwide, taking a crucial step towards reducing the impact of this deadly disease on vulnerable populations.”
Bharat Biotech executive chairman Dr Krishna Ella said, “This collaboration between BBIL and BBio exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation’s mission to eradicate polio.”
“Oral polio vaccines have been an integral part of the government of India’s universal immunisation programme (UIP) for several decades, with Bharat Biotech being one of the largest suppliers to immunisation programmes across the world,” Dr Ella added.
The two players said as the world approaches the critical phase of global polio eradication, this collaboration will support the effort to create a polio-free world.
Bharat Biotech and Bilthoven Biologicals, who have entered into an agreement, will jointly obtain the regulatory approvals and licenses required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at Bilthoven Biologicals, a joint statement by Bharat Biotech and SII said.
Commenting on the development, SII CEO Adar Poonawalla said “We are delighted to join forces with Bharat Biotech to reinforce the global supply of polio vaccines. Our vision is to eradicate polio worldwide, taking a crucial step towards reducing the impact of this deadly disease on vulnerable populations.”
Bharat Biotech executive chairman Dr Krishna Ella said, “This collaboration between BBIL and BBio exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation’s mission to eradicate polio.”
“Oral polio vaccines have been an integral part of the government of India’s universal immunisation programme (UIP) for several decades, with Bharat Biotech being one of the largest suppliers to immunisation programmes across the world,” Dr Ella added.
The two players said as the world approaches the critical phase of global polio eradication, this collaboration will support the effort to create a polio-free world.
[ad_2]
Source link
